| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC2838 |
| Trial ID | NCT05117008 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA CAR-T cells |
| Co-treatment | belantamab mafodotin |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Maintenance Belantamab Mafodotin (Blenrep) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma |
| Year | 2021 |
| Country | United States |
| Company sponsor | Medical College of Wisconsin |
| Other ID(s) | PRO00042276 |
| Cohort 1 | |||||||
|
|||||||